New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital

April 10, 2024

https://www.globenewswire.com/news-release/2024/04/10/2860748/0/en/New-Publication-in-Brain-Stimulation-Confirms-Full-TMS-Treatment-Course-Is-Vital.html

MALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced the publication of significant clinical findings in Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation, the premier journal in the field of neuromodulation. This analysis concludes that while early symptom improvement in major depressive disorder (MDD) is strongly predictive of response at the completion of transcranial magnetic stimulation (TMS) treatment (36 sessions), lack of early improvement does not predict final treatment outcome. 

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.